Nothing Special   »   [go: up one dir, main page]

PT2925757T - Compostos e composições para o tratamento de doenças parasitárias - Google Patents

Compostos e composições para o tratamento de doenças parasitárias

Info

Publication number
PT2925757T
PT2925757T PT137959771T PT13795977T PT2925757T PT 2925757 T PT2925757 T PT 2925757T PT 137959771 T PT137959771 T PT 137959771T PT 13795977 T PT13795977 T PT 13795977T PT 2925757 T PT2925757 T PT 2925757T
Authority
PT
Portugal
Prior art keywords
compositions
compounds
treatment
parasitic diseases
parasitic
Prior art date
Application number
PT137959771T
Other languages
English (en)
Inventor
Kumar Chatterjee Arnab
Suresh Nagle Advait
Paraselli Prasuna
Reddy Kondreddi Ravinder
Yong Leong Seh
Kumar Mishra Pranab
Joseph Moreau Robert
Thomas Roland Jason
Lin Sandra Sim Wei
Simon Oliver
Jocelyn Tan Liying
Ks Yeung Bryan
Zou Bin
Bollu Venkatataiah
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2925757T publication Critical patent/PT2925757T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT137959771T 2012-11-19 2013-11-18 Compostos e composições para o tratamento de doenças parasitárias PT2925757T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728018P 2012-11-19 2012-11-19
US201361847860P 2013-07-18 2013-07-18

Publications (1)

Publication Number Publication Date
PT2925757T true PT2925757T (pt) 2018-01-09

Family

ID=49667630

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137959771T PT2925757T (pt) 2012-11-19 2013-11-18 Compostos e composições para o tratamento de doenças parasitárias

Country Status (19)

Country Link
US (3) US9556169B2 (pt)
EP (1) EP2925757B1 (pt)
JP (1) JP6298472B2 (pt)
CN (1) CN105164124B (pt)
AR (1) AR093532A1 (pt)
CY (1) CY1119727T1 (pt)
DK (1) DK2925757T3 (pt)
ES (1) ES2655030T3 (pt)
HR (1) HRP20171998T1 (pt)
HU (1) HUE037600T2 (pt)
LT (1) LT2925757T (pt)
ME (1) ME03042B (pt)
PL (1) PL2925757T3 (pt)
PT (1) PT2925757T (pt)
RS (1) RS56720B1 (pt)
SI (1) SI2925757T1 (pt)
TW (1) TWI600654B (pt)
UY (1) UY35146A (pt)
WO (1) WO2014078802A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
BR112018014957A2 (pt) 2016-01-21 2019-04-16 Novartis Ag compostos e composições para o tratamento de criptosporidiose
TWI679197B (zh) * 2016-05-05 2019-12-11 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018071836A1 (en) * 2016-10-13 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
MA52337A (fr) 2017-03-01 2021-03-03 Anacor Pharmaceuticals Inc Nouveaux analogues d'oxaborole et utilisations de ces derniers
IL269390B (en) * 2017-03-20 2022-08-01 Broad Inst Inc Preparations and methods for the treatment of parasitic diseases
CN117105827A (zh) 2017-03-27 2023-11-24 魁北克电力公司 用于电解质组合物中或用作电极添加剂的盐
CN107037148B (zh) * 2017-04-07 2019-11-19 上海药明康德新药开发有限公司 卤泛曲林的高效液相检测方法
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US20220048903A1 (en) * 2018-07-09 2022-02-17 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic Heterocyclic Compounds
GB201811695D0 (en) * 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
PE20220281A1 (es) 2019-03-19 2022-02-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
CA3141905A1 (en) * 2019-06-07 2020-12-10 Elanco Tiergesundheit Ag Bicyclic derivatives for treating endoparasites
KR20230028268A (ko) 2020-05-29 2023-02-28 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 헤테로시클릭 화합물
WO2023275590A1 (en) 2021-06-29 2023-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Detection of phosphoinositides in blood cells as a biomarker for alpha synuclein associated pathologies and a method of treatment of parkinson's disease and the related neurodegenerations
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
KR20240112282A (ko) 2021-11-01 2024-07-18 베링거잉겔하임베트메디카게엠베하 구충제 피롤로피리다진 화합물
CA3181279A1 (en) * 2022-03-24 2023-09-24 Bloom Energy Corporation Fuel cell stack assembly including heat sink inserts
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024196989A1 (en) * 2023-03-20 2024-09-26 University Of Central Florida Research Foundation, Inc. Anti-malarial therapy
WO2024213663A1 (en) * 2023-04-13 2024-10-17 Syngenta Crop Protection Ag Pyrazolo[1,5-a]pyridine derivatives

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
KR20010014183A (ko) 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
JP2001139575A (ja) 1999-11-15 2001-05-22 Fujisawa Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002312D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
JP2003525291A (ja) * 2000-03-01 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２，４−二置換チアゾリル誘導体
DE60103752T2 (de) 2000-04-28 2005-07-14 Glaxo Group Ltd., Greenford Verfahren zur herstellung von pyrazolopyridinderivaten
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
DE60227794D1 (de) 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AUPR916301A0 (en) 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4500055B2 (ja) 2002-04-23 2010-07-14 塩野義製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体およびそれを含有するＮＡＤ（Ｐ）Ｈオキシダーゼ阻害剤
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2003268156A1 (en) 2002-09-17 2004-04-08 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1778676B1 (en) 2004-07-16 2010-08-25 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
US7465726B2 (en) 2004-08-02 2008-12-16 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2.3-B]pyridines
WO2006044509A2 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JP4935357B2 (ja) 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
DE602005014382D1 (de) * 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
EP1832588A4 (en) 2004-12-28 2009-09-02 Takeda Pharmaceutical IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF
US7713975B1 (en) 2005-01-12 2010-05-11 Alcon, Inc. 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2407453A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. PGD2 receptor antagonist
US20070129364A1 (en) 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
WO2007065664A2 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
WO2007086080A2 (en) 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2007221135A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
EP2038279A2 (en) 2006-06-06 2009-03-25 Avigen, Inc. Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
EP2063962A2 (en) 2006-09-07 2009-06-03 Biogen Idec MA Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
US20100093760A1 (en) 2006-09-12 2010-04-15 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CN101600718B (zh) 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
AU2008210904A1 (en) 2007-01-26 2008-08-07 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of Plasmodium related diseases
WO2008156783A2 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
AU2008273050A1 (en) 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
WO2009012482A2 (en) 2007-07-19 2009-01-22 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2009218459A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
EA019507B1 (ru) 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
JP2009298710A (ja) 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾ［１，２−ｂ］ピリダジン誘導体含有医薬組成物
KR20180018839A (ko) 2008-06-30 2018-02-21 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
US8518911B2 (en) 2008-08-05 2013-08-27 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyridines as MARK inhibitors
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
BRPI0919085B1 (pt) 2008-09-24 2021-05-11 Basf Se métodos não terapêuticos para controlar pragas invertebradas e para proteger material de propagação de plantas e/ou plantas que se desenvolvem dos mesmos, compostos de pirazol ou um sal ou um n-óxido dos mesmos, e, composição agrícola
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2376490B1 (en) 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
WO2010074586A1 (en) 2008-12-23 2010-07-01 Pathway Therapeutics Limited Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
EP2408753A4 (en) 2009-03-20 2012-11-07 Univ Brandeis COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
US8927545B2 (en) 2009-03-30 2015-01-06 Duke University Inhibiting Eph B-3 kinase
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
AR077463A1 (es) * 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
RU2421455C2 (ru) 2009-07-14 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TW201113286A (en) 2009-09-03 2011-04-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
EP2480548A4 (en) 2009-09-23 2013-02-20 Panmira Pharmaceuticals Llc INDOLIZIN 5-LIPOXYGENASE INHIBITORS
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
EP2925757B1 (en) 2017-10-04
ME03042B (me) 2018-10-20
HUE037600T2 (hu) 2018-09-28
US9556169B2 (en) 2017-01-31
US9926314B2 (en) 2018-03-27
US20180230145A1 (en) 2018-08-16
WO2014078802A1 (en) 2014-05-22
US20150344471A1 (en) 2015-12-03
TW201429967A (zh) 2014-08-01
US20160333012A1 (en) 2016-11-17
RS56720B1 (sr) 2018-03-30
DK2925757T3 (en) 2018-01-15
SI2925757T1 (en) 2018-01-31
EP2925757A1 (en) 2015-10-07
PL2925757T3 (pl) 2018-06-29
AR093532A1 (es) 2015-06-10
CY1119727T1 (el) 2018-06-27
CN105164124B (zh) 2017-03-15
UY35146A (es) 2014-06-30
JP2016505529A (ja) 2016-02-25
HRP20171998T1 (hr) 2018-02-09
CN105164124A (zh) 2015-12-16
ES2655030T3 (es) 2018-02-16
LT2925757T (lt) 2017-12-27
JP6298472B2 (ja) 2018-03-20
TWI600654B (zh) 2017-10-01

Similar Documents

Publication Publication Date Title
HUE037600T2 (hu) Vegyületek és készítmények paraziták által okozott fertõzések kezelésére
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
HK1212632A1 (zh) 用於治療 介導的疾病的藥物組合物
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
HK1213798A1 (zh) 治療性化合物和組合物
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
EP2827856A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES
EP2773342A4 (en) COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
HK1205502A1 (en) Compounds for the treatment of mtor pathway related diseases mtor
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
SG11201404649UA (en) Novel compounds for the treatment of dyslipidemia and related diseases
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
IL238592B (en) Compounds for the treatment of liver diseases
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
HK1157189A1 (en) Pharmaceutical composition for the treatment of tumor diseases
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds